

Confirmed Speakers

Inaugural Lecture

Inaugural Lecture Toward Universal Druggability (PL01)



Prof. Gregory L. VERDINE
(CO-FOUNDER, PRESIDENT AND CEO LIFEMINE THERAPEUTICS, Cambridge, MA, United States)

Plenary Speakers

Gut Feeling: Illuminating Atypical Stress-sensing Mechanisms in the Gut Empowers New Therapeutic Opportunities (PL06)



Prof. Yimon AYE
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

Synthetic and Medicinal Chemistry for Biologics (PL16)



Prof. Jeffrey BODE
(ETH ZURICH, Zürich, Switzerland)

Modern Modelling Techniques to Aid Structure-Based Drug Design (PL03)



Dr Massimiliano BONOMI
(INSTITUT PASTEUR, Paris, France)

How Degraders Work: Molecular Recognition and Design Principles (PL11)



Prof. Alessio CIULLI
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

Toward a Holistic Drug Discovery Approach - How Chemical Biology & Novel Technologies Support the Identification & Development of Drug Candidates (PL08)



Dr Uwe GRETHER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Expanding the Chemical Toolbox of E3 Ligase Ligands for PROTAC Design (PL12)



Prof. Michael GUTSCHOW
(UNIVERSITY OF BONN, Bonn, Germany)

Advancements in Drug-like Cyclic Peptides: A Pathway to Orally Available KRAS Inhibitor (PL13)



Dr Satoshi HASHIMOTO
(CHUGAI PHARMACEUTICAL, Kanagawa, Japan)

Confirmed Speakers

Title to be announced (PL04)



Prof. Akane KAWAMURA
(NEWCASTLE UNIVERSITY, Newcastle, United Kingdom)

Title to be announced (PL09)



Dr Angela MACKAY
(NOVARTIS PHARMA AG, Basel, Switzerland)

Recent Advances in DNA-Encoded Library Technologies at GSK (PL17)




Dr Lisa MARCAURELLE
(GSK, Cambridge, United States)

The Discovery of a GPCR Antagonist as Clinical Candidate for Autoimmune Diseases (PL14)



Dr Emmanuel MEYER
(ETH, Basel, Switzerland)

Tools and Tactics for Targeting RNA with Small Molecules (PL02)



Dr Jay SCHNEEKLOTH
(NATIONAL CANCER INSTITUTE, Frederick, United States)

Vaccines, Antibody Therapies and Diagnostics Based on Synthetic Carbohydrates (PL18)



Prof. Peter H. SEEBERGER
(MAX PLANCK INSTITUTE OF COLLOIDS AND INTERFACES, Berlin, Germany)

Exploring PTM Chemical Biology for Drug Discovery (PL07)



Prof. Edward TATE
(IMPERIAL COLLEGE LONDON, London, United Kingdom)

Molecular Switches for Gene Control (PL05)



Prof. Olalla VÁZQUEZ
(PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany)

Design, Synthesis and Evaluation of PET Tracers Targeting alpha-Synuclein, a Rational Approach (PL10)



Prof. Bert WINDHORST
(VU UNIVERSITY MEDICAL CENTER, Amsterdam, The Netherlands)

Confirmed Speakers

Short Lectures

Discovering Novel Inhibitors of Wild-type and Acquired Drug-resistant Mutant Forms of c-MET (SL06)



Dr Gavin W. COLLIE
(ASTRAZENECA, Cambridge, United Kingdom)

New Modalities Enabling Target Validation (SL03)



Dr Werngard CZECHTIZKY
(ASTRAZENECA, Mölndal, Sweden)

Cryo-EM at AstraZeneca: Enabling SBDD in Challenging Multiprotein Targets (SL02)



Dr Taiana MAIA DE OLIVEIRA
(ASTRAZENECA PLC, Cambridge, United Kingdom)

Induced-Volatolomics, a New Research Field in Chemical Biology (SL04)



Dr Pauline POINOT
(UNIVERSITY OF POITIERS, Poitiers, France)

Discovery of Novel Small Molecules Binders of Soluble Mutant HTT & Derivatization into PROTACs (SL05)



Dr Geoffrey SCHWERTZ
(UCB BIOPHARMA, Braine l'Alleud, Belgium)

Small-Molecule Inhibitors of RNA-binding Proteins Regulating m6A RNA Methylation (SL01)



Dr Peng WU
(MAX-PLANCK-INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)